



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Fig. 1. The image shows a rash consisting of 0.3 to 1.5 cm in diameter round and oval erythematous scaly plaques with peripheral collarette scaling.

basis. Presented with a 7-day history of itchy rash. On examination, an eruption consisting of round and oval erythematous squamous plaques with a peripheral scaling collarette, with distribution on the trunk and upper limbs, leaving the palms, soles, and facial area clean (Fig. 1). There was no evidence of a plaque or herald patch. Close contact at home with 3 relatives with compatible symptoms of mild COVID infection (fever, cough, diarrhoea, and anosmia), however, she had remained asymptomatic, except for the skin condition previously described. Although the patient's symptoms and examination suggested a Pityriasis Rosea Gibert, the epidemic environment of COVID-19 and its diversity of skin manifestations, made us think of a possible skin condition caused by the SARS-CoV-2 virus. We recommended the patient to be isolated for 14 days from the beginning of the symptoms, as established by the Spanish Ministry of Health,¹ in addition to skin moisturizing measures in combination with a topical corticoid in the most pruritic lesions. Twenty days after the start of the symptoms, the presence of SARS-CoV-2 nucleic acids (PCR) was detected in a nasopharyngeal swab. Hematology, biochemistry, venous blood gas, and coagulation parameters including ferritin, C-reactive protein, lactate dehydrogenase and D-dimer were in normal ranges. The progression of the condition was excellent, with the lesions returning within 2 weeks of the onset and almost completely disappearing after 30 days.

A recent study conducted in Italy by Recalcati S³ revealed that 20.4% of patients hospitalized with COVID-19 developed cutaneous manifestations, some of them at the beginning of the disease and others after hospitalization. Reported manifestations are generalized erythema, hives, *livedo reticularis* and acro-ischemia (*chilblain-like*). We consider that this clinical case provides relevant information to doctors, since it shows a patient with exclusively cutaneous Covid-19-related symptoms of unusual appearance.

Funding

This study has not received external funding.

References

1. Linares M., Santos Larrégola L., Santo González A., Arranz Izquierdo J., Molero J.M., Jorge Bravo M.T., et al. Documento técnico. Manejo en atención primaria del COVID-19. Ministerio de Sanidad. Gob España [Accessed 17 March 2020] Available from: https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-China/documentos/Manejo_primaria.pdf.
2. Marinosci A, Landis BN, Calmy A. Possible link between anosmia and COVID-19: sniffing out the truth. *Eur Arch Otorhinolaryngol*. 2020:1–2, <http://dx.doi.org/10.1007/s00405-020-05966-0>.
3. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. *J Eur Acad Dermatol Venereol*. 2020, <http://dx.doi.org/10.1111/jdv.16387>.

David Martín Enguix^{a, ⁎}, María del Carmen Salazar Nieves^b, Divina Tatiana Martín Romero^c

^a *Medicina Familiar y Comunitaria, Centro de Salud Fortuny Velutti, Granada, Spain*

^b *Servicio de Dermatología, Hospital Universitario Virgen de las Nieves, Granada, Spain*

^c *Servicio de Medicina Preventiva y Salud Pública, Hospital Universitario Clínico San Cecilio, Granada, Spain*

* Corresponding author.

E-mail address: davidm123m45@hotmail.com (D. Martín Enguix).

<https://doi.org/10.1016/j.medcle.2020.05.017>

2387-0206/ © 2020 Elsevier España, S.L.U. All rights reserved.